Antithrombotic Therapy in PAD: From Acute to Chronic Care
- Have increased knowledge regarding the
- Latest clinical data on the use of factor Xa inhibitor therapy in patients with peripheral artery disease (PAD)
- Have greater competence related to
- Use of antithrombotic therapy in patients with PAD who have undergone a recent procedure
Professor of Medicine
Duke University Medical Center
Durham, North Carolina
Associate Professor of Medicine
Director Vascular Research
University of Colorado School of Medicine
Executive Director; CPC Clinical Research
Department of Medicine
Section of Cardiology
University of Chicago Medicine
As a provider accredited by the ACCME, The University of Chicago Pritzker School of Medicine asks everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. This includes any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months, including financial relationships of a spouse or life partner that could create a conflict of interest. Mechanisms are in place to identify and resolve any potential conflict of interest prior to the start of the activity.
Additionally, The University of Chicago Pritzker School of Medicine requires authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.